Table 1. (KRAS mutant) Patient and Disease Characteristics at Baseline.

	Overall (N = 394)		KRAS mutant (N = 169)				KRAS wild type (N = 225)
			Patients who had used oxaliplatin-based regimens (N = 131)		Never-used oxaliplatin-based regimens (N = 38)		Patients who had used oxaliplatin-based regimens (N = 185)		Never-used oxaliplatin-based regimens (N = 40)
Characteristics	No. of patients	%	No. of patients	%	No. of patients	%	No. of patients	%	No. of patients	%
Sex
Male	228	58	59	45	19	50	121	65	29	73
Female	166	42	72	55	19	50	64	35	11	27
Age, years
Median	62		62		63		61		64
Range	23–91		24–87		34–91		25–84		23–88
≥65	156	40	52	40	17	45	68	37	19	48
<65	238	60	79	60	21	55	117	63	21	52
Agents had been-used
Irinotecan	319	81	105	80	33	87	150	81	31	78
fluoropyrimidines	394	100	131	100	38	100	185	100	40	100
Cetuximab	177	45	37	28	6	16	121	65	13	33
Bevacizumab	203	52	77	59	26	68	77	42	23	58
Tumor site
Proximal1	121	31	43	33	18	50	43	23	17	43
Distal2	273	69	88	67	18	50	142	77	23	57
No. of metastatic sites
1	288	73	90	69	28	74	145	78	25	63
≥ 2	106	27	41	31	10	26	40	22	15	37
Initial stage
I–III	152	39	53	40	28	74	52	28	19	48
IV	242	61	78	60	10	26	133	72	21	52

1: Proximal indicates cecum, ascending colon, hepatic flexure, and transverse colon. 2: Distal indicates splenic flexure, descending colon, sigmoid colon, and rectum.